Lonza and Moderna Collaborate for Drug Substance Manufacturing

Lonza and Moderna Collaborate for Drug Substance Manufacturing

Author: ChemistryViews

Lonza and Moderna will expand their collaboration to further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna with a new production line at Lonza’s site in Geleen, the Netherlands. The new mRNA production line will contribute to the supply of up to 300 million additional doses per year at a dose of 50ug at full capacity.

In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to manufacture Moderna’s COVID-19 vaccine and other future Moderna products. Since then, Lonza has installed three production lines at its site in Visp, Switzerland, and one production line in Portsmouth, USA. In April 2021, Lonza and Moderna entered into a new agreement to install three additional production lines at the Visp site.

The new production line in Geleen is expected to be operational by the end of 2021. Lonza will use its existing infrastructure in Geleen to enable a fast build-out and ramp-up of operations.



Also of Interest

  • Collection: SARS-CoV-2 Virus
    What we know about the new coronavirus and COVID-19

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *